FUJIFILM Diosynth Biotechnologies Kicks Off First Phase of Major Global Expansion

FUJIFILM Diosynth Biotechnologies is excited to announce a significant milestone at its Hillerød site, as it begins the first phase of its expansion. Known globally for its expertise in contract development and manufacturing of biologics, vaccines, and advanced therapies, the company is now set to enhance its production capacity to help meet the growing demand for life-saving medicines. This expansion adds six new mammalian cell bioreactors, doubling the site's capacity to a total of 12 x 20,000 L bioreactors. 

The next phase, backed by a major investment, will bring even more capacity, including an additional 8 x 20,000 L bioreactors and two new downstream processing streams. By mid-2025, the site will also begin fill/finish production, with full expansion expected by 2026. This growth will not only increase the site size to 51,500 m² but also create up to 2,200 new jobs, contributing significantly to the local economy and the global healthcare ecosystem. FUJIFILM Diosynth is excited to continue expanding its capabilities, with a long-term vision to strengthen the delivery of essential medicines worldwide.

Since 2011, FUJIFILM Corporation has committed over $8 billion to build a robust, global network focused on biologics manufacturing. This network includes highly flexible modular facilities that are designed to rapidly scale production in response to market needs. Looking ahead to 2025, FUJIFILM Diosynth Biotechnologies will open the first phase of its state-of-the-art facility in Holly Springs, North Carolina. This move is a key part of the company’s ongoing dedication to expanding its global ecosystem and meeting the growing demand for life-saving biologic medicines.

Christian Houborg, site head and senior vice president of FUJIFILM Diosynth Biotechnologies, said in a statement, “Our operations in Hillerød represent our commitment to being the world-leading partner for life — supporting our customers and their patients globally. This expansion is a testament to our vision for introducing robust capabilities into the global biopharma landscape, ensuring the timely delivery of critical therapies to those in need.” 

Lars Petersen, president and chief executive officer, FUJIFILM Diosynth Biotechnologies, mentioned, “The Hillerød facility is the first expansion in our global network, which will include further developments in the US, UK, and Japan. By investing in state-of-the-art facilities on both sides of the Atlantic and prioritising our workforce, we are uniquely positioned to meet the evolving needs of our partners and the patients they serve. This is just the beginning. With our Partners for Life strategy, we are dedicated to fulfilling our promises and ensuring that our global network supports the production of the life-impacting medicines that make patients’ lives better. 

This expansion is also a key step in FUJIFILM Diosynth Biotechnologies' commitment to sustainability through its "Partners for the Planet" initiative. By integrating eco-friendly practices into all of its operations, the Hillerød site has secured a ten-year Power Purchase Agreement to exclusively source electricity from renewable energy. This sustainable approach has earned the site a silver certification from the internationally respected EcoVadis standard.